scPharmaceuticals announced the launch and commercial availability of FUROSCIX, a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association Class II and Class III chronic heart failure. FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema. The FUROSCIX Infusor will deliver only an 80-mg dose. Management will provide an update on this and other recent developments during its regularly scheduled fourth quarter 2022 earnings conference call and webcast in March.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SCPH:
- scPharmaceuticals reports inducement grants under Nasdaq listing rule
- scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
- scPharmaceuticals targets Feb 20 for commercial availability of FUROSCIX
- scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update